The Global Fund to Fight AIDS, Tuberculosis and Malaria today approved US$ 15 million for the malaria vaccine pilots, assuring full funding for the first phase of the programme.
Earlier this year, Gavi, the Vaccine Alliance and UNITAID announced commitments of up toUS$ 27.5 million and US$ 9.6 million, respectively, for the first 4 years of the vaccine programme.
RTS,S was developed through a partnership between GlaxoSmithKline and the PATH Malaria Vaccine Initiative (MVI), with support from the Bill & Melinda Gates Foundation and from a network of African research centres.
“WHO recognizes and commends the leadership and support of all funding agencies and partners who have made this achievement possible,” said Dr Jean-Marie Okwo-Bele, Director of the WHO Department of Immunization, Vaccines and Biologicals.
14295
世卫组织两个咨询机构推荐的疫苗计划
Vaccine programme recommended by twoWHOadvisory bodies
In October 2015, two independent WHO advisory groups comprised of the world’s foremost experts on vaccines and malaria – the Strategic Advisory Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory Committee (MPAC) – recommended pilot implementation of the RTS,S vaccine in 3 to 5 settings in sub-Saharan Africa.
These recommendations followed a July 2015 announcement that the European Medicines Agency (EMA) had issued a positive scientific opinion of the RTS,S vaccine.
WHO officially adopted the SAGE-MPAC recommendations in January 2016 and has since worked to mobilize financial support for the pilots and to finalize the programme design.
14299
试点计划将对提供所需4剂“RTS,S”疫苗的可行性；
The pilot programme will evaluate the feasibility of delivering the required 4 doses of RTS,S; the impact of RTS,S on lives saved; and the safety of the vaccine in the context of routine use.
14300
“RTS,S”疫苗对挽救生命产生的影响；
* It will also assess the extent to which the vaccine’s protective effect demonstrated in children aged 5–17 months old in the Phase 3 trial can be replicated in real-life settings.